• PDF: Delivered by email usually within 12 to 24 UK business hours.

Neurologix, Inc.
Product Pipeline Review 2012

Neurologix, Inc. Product Pipeline Review 2012

  • FOCUS
    • Neurologix, Inc.
  • SUMMARY
    • Global Market Directs pharmaceuticals report, Neurologix, Inc. Product Pipeline Review 2012 provides data on the Neurologix, Inc.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
    • This report is built using data and information sourced from Global Markets Directs proprietary databases, Neurologix, Inc.s corporate website, SEC filings, investor presentations and featured press releases, both from Neurologix, Inc. and industry-specific third party sources, put together by Global Markets Directs team.
  • SCOPE
    • Neurologix, Inc. Brief Neurologix, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
    • Review of current pipeline of Neurologix, Inc. human therapeutic division.
    • Overview of pipeline therapeutics across various therapy areas.
    • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
    • Product profiles for late stage and clinical stage products of Neurologix, Inc. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
    • Recent updates of the Neurologix, Inc.s pipeline in the last quarter.
    • Key discontinued and dormant projects.
    • Latest news and deals relating to the products.
  • REASONS TO BUY
    • Evaluate Neurologix, Inc.s strategic position with total access to detailed information on its product pipeline.
    • Assess the growth potential of Neurologix, Inc. in its therapy areas of focus.
    • Identify new drug targets and therapeutic classes in the Neurologix, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
    • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
    • Exploit collaboration and partnership opportunities with Neurologix, Inc..
    • Avoid Intellectual Property Rights related issues.
    • Explore the dormant and discontinued projects of Neurologix, Inc. and identify potential opportunities in those areas.
    • This report covers the following industry codes:
    • SIC Code: 2834
    • NAICS Code: 325412
  • CONTENTS
    • Neurologix, Inc. Snapshot
    • Neurologix, Inc. Overview
    • Key Information
    • Key Facts
    • Neurologix, Inc. - Research and Development Overview
    • Key Therapeutic Areas
    • Neurologix, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Neurologix, Inc. - Pipeline Products Glance
    • Neurologix, Inc. - Late Stage Pipeline
    • Phase III Products/Combination Treatment Modalities
    • Neurologix, Inc. - Drug Profiles
    • Humanin Gene Therapy
    • Product Description
    • Mechanism of Action
    • R and D Progress
    • Neurologix, Inc. - Pipeline Analysis
    • Neurologix, Inc. - Pipeline Products by Therapeutic Class
    • Neurologix, Inc. - Recent Pipeline Updates
    • Neurologix, Inc. - Dormant Projects
    • Neurologix, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
    • Drug For Depression
  • NLX-P101
    • rAAV-NPY
    • Neurologix, Inc. - Company Statement
    • Neurologix, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations and Subsidiaries
    • Neurologix, Inc., Recent Developments
    • Neurologix, Inc.- Press Release
    • Dec 03, 2009: Neurologix Completes All Surgical Procedures in Its Clinical Trial for Parkinson's Disease
    • Jan 23, 2009: Neurologix Commences Its Phase II Clinical Trial Of Novel Gene Transfer Approach For Treatment Of Parkinson's Disease
    • Jan 21, 2009: Neurologix Commences Its Phase 2 Clinical Trial Of Novel Gene Transfer Approach For Treatment Of Parkinson's Disease
    • Financial Deals Landscape
    • Neurologix, Inc., Deals Summary
    • Neurologix, Inc., Pharmaceuticals and Healthcare, Deal Details
    • Licensing Agreements
    • Neurologix Enters Into Licensing Agreement With Cornell University
    • Neurologix Signs Licensing Agreement With Aegera Therapeutics
    • Diamyd Therapeutics Enters Into Licensing Agreement With Neurologix
    • Equity Offering
    • Neurologix Completes $5 Million Private Placement Of Series D Convertible Preferred Stock
    • Neurologix Completes Private Placement Of Series C Preferred Stock For $12 Million
    • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
  • LIST OF TABLES
    • Neurologix, Inc., Key Information
    • Neurologix, Inc., Key Facts
    • Neurologix, Inc. - Pipeline by Indication, 2012
    • Neurologix, Inc. - Pipeline by Stage of Development, 2012
    • Neurologix, Inc. - Monotherapy Products in Pipeline, 2012
    • Neurologix, Inc. - Phase III, 2012
    • Neurologix, Inc. - Pipeline By Therapeutic Class, 2012
    • Neurologix, Inc. - Recent Pipeline Updates, 2012
    • Neurologix, Inc. - Dormant Developmental Projects,2012
    • Neurologix, Inc. - Discontinued Pipeline Products, 2012
    • Neurologix, Inc., Subsidiaries
    • Neurologix, Inc., Deals Summary
    • Neurologix Enters Into Licensing Agreement With Cornell University
    • Neurologix Signs Licensing Agreement With Aegera Therapeutics
    • Diamyd Therapeutics Enters Into Licensing Agreement With Neurologix
    • Neurologix Completes $5 Million Private Placement Of Series D Convertible Preferred Stock
    • Neurologix Completes Private Placement Of Series C Preferred Stock For $12 Million
  • LIST OF TABLES
    • Neurologix, Inc. - Pipeline by Indication, 2012
    • Neurologix, Inc. - Pipeline by Stage of Development, 2012
    • Neurologix, Inc. - Monotherapy Products in Pipeline, 2012
+44 20 8816 8548

Ask a question about Neurologix, Inc.

Enter the characters you see in the picture below
Captcha